The demographic status and seroprevalence of SARS-CoV-2 antibodies in B- thalassemia patients
DOI:
https://doi.org/10.48047/HM.10.2.2024.1480-1490Keywords:
Beta thalassemia, Covid 19, SARSCoV-2, Iron, PakistanAbstract
Beta thalassemia is a blood disorder in which there is mutation in gene encoding for betaglobin chain. Reduced or absent beta globin chain lead to ineffective erythropoiesis and immature red blood cell production. Covid 19 also known as SARSCoV-2 causes acute respiratory infectious disease that transmits through respiratory droplets. People with underlying secondary conditions are more prone towards developing severe form of the virus. This study investigates the prevalence of SARS-CoV-2 antibodies in patients with β-thalassemia major (β-TM) in Pakistan, focusing on the impact of iron chelation therapy and associated comorbidities on COVID-19 outcomes. This work involved 200 β-TM patients aged 10 to 30 years. Blood samples were collected and analyzed for hematological, biochemical, and immunological parameters. The study highlights the complex interaction between iron overload, common in β-TM patients due to frequent transfusions, and susceptibility to severe COVID-19. The role of iron chelation therapy, which has antiviral properties, was also examined. Despite the lack of a direct link between hemoglobinopathies and respiratory diseases, underlying conditions such as cardiac, liver, and renal diseases, exacerbated by iron accumulation, were found to increase the risk of severe COVID-19 outcomes. In conclusion, addressing the unique challenges faced by thalassemia patients in the context of COVID-19 requires a multifaceted approach. A robust data system and targeted research will be vital in developing strategies for prevention, treatment, and long-term care for this vulnerable group.
Downloads
References
Al-Zwaini IJ. Thalassemia and Other Hemolytic Anemias: BoD–Books on Demand; 2018.
Zaheer HA, Waheed U, Abdella YE, Konings F. Thalassemia in Pakistan: A forward-looking solution to a serious health issue. Global Journal of Transfusion Medicine. 2020;5(1):108.
Fani M, Teimoori A, Ghafari S. Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virology. 2020;15(5):317-23.
Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19): Springer; 2020. p. 23-31.
Almanar MA. The shifting of face to face learning to distance learning during the pandemic Covid-19. Globish: An English-Indonesian Journal for English, Education, and Culture. 2020;9(2):111-8.
Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation. European Journal of Haematology. 2020;105(4):378-86.
Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A. Immunological evaluation of beta-thalassemia major patients receiving oral iron chelator deferasirox. J Coll Physicians Surg Pak. 2014;24(7):467-71.
Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunologic research. 2020:1-12.
Sumbal MA, Mehmood SS, Ali H, Fayyaz T, Faisal M. CROSS ANTIGENICITY OF SALMONELLA TYPHI AND NOVEL CORONAVIRUS ANTIBODY IN SECOND WAVE OF COVID-19 PANDEMIC. 2022.
Tsatsakis A, Vakonaki E, Tzatzarakis M, Flamourakis M, Nikolouzakis TK, Poulas K, et al. Immune response (IgG) following full inoculation with BNT162b2 COVID‑19 mRNA among healthcare professionals. International Journal of Molecular Medicine. 2021;48(5):1-10.
Dong T, Wang M, Liu J, Ma P, Pang S, Liu W, et al. Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives. Chemical Science. 2023;14(23):6149-206.
Drefahl S, Wallace M, Mussino E, Aradhya S, Kolk M, Brandén M, et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. Nature communications. 2020;11(1):5097.
Javed W, Abidi SHB, Baqar JB. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms. BMC Infectious Diseases. 2022;22(1):481.
Taher AT, Bou‐Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations. American Journal of Hematology. 2020;95(8):E208.
Galbadage T, Peterson BM, Awada J, Buck AS, Ramirez DA, Wilson J, et al. Systematic review and meta-analysis of sex-specific COVID-19 clinical outcomes. Frontiers in medicine. 2020;7:348.
Zhang F, Yang D, Li J, Gao P, Chen T, Cheng Z, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study. MedRxiv. 2020:2020.03. 21.20040121.
Aleem MT, Munir F, Shakoor A, Gao F. mRNA vaccines against infectious diseases and future direction. International Immunopharmacology. 2024;135:112320.
Oymak Y, Karapinar TH. COVID-19 pandemic and thalassemia major patients: Transfusion practice and treatment assessment. Journal of Pediatric Hematology/Oncology. 2021;43(8):e1073-e6.
Fung TS, Liao Y, Liu DX. Regulation of stress responses and translational control by coronavirus. Viruses. 2016;8(7):184.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
